BACKGROUND: Magnesium is an essential ion for all living cells because over 300 enzymes require the presence of magnesium for their catalytic action. To date, no group has evaluated magnesium as a cardiovascular risk factor in chronic kidney disease (CKD) subjects, in which closely interrelated factors and potential confounders such as endothelial dysfunction, insulin resistance (the homeostasis model assessment (HOMA) index) and inflammation (expressed as serum C-reactive protein (CRP) levels) were also considered. METHODS: Between March 2006 and December 2010, 283 CKD patients were followed up for time-to-event analysis until the occurrence of fatal or nonfatal cardiovascular events. Endothelium-dependent vasodilatation (flow-mediated dilatation; FMD) and endothelium-independent vasodilatation (nitroglycerin-mediated dilatation) of the brachial artery were assessed noninvasively using high-resolution ultrasound. RESULTS: From the univariate analysis of FMD, it appears that a higher magnesium level is associated with less endothelial dysfunction. When a multivariate analysis was performed, magnesium and estimated glomerular filtration rates (eGFR) maintained a strong positive correlation with FMD, supporting the hypothesis that higher levels of magnesium may protect against endothelial damage. In univariate Cox proportional hazards models, FMD, magnesium, high sensitivity CRP, the HOMA index, eGFR, comorbid diabetes, hypertension, smoking status, systolic blood pressure, serum phosphate and intact parathormone emerged as significant predictors for cardiovascular outcomes. Kaplan-Meier curves showed significantly higher cardiovascular mortality rates in CKD patients whose serum magnesium levels were below 2.05 mg/dl. CONCLUSIONS: This observational cohort study showed that magnesium may be an independent predictor of future cardiovascular outcomes and is the first study demonstrating such a role in etiologically diagnosed CKD patients, across different stages.
BACKGROUND:Magnesium is an essential ion for all living cells because over 300 enzymes require the presence of magnesium for their catalytic action. To date, no group has evaluated magnesium as a cardiovascular risk factor in chronic kidney disease (CKD) subjects, in which closely interrelated factors and potential confounders such as endothelial dysfunction, insulin resistance (the homeostasis model assessment (HOMA) index) and inflammation (expressed as serum C-reactive protein (CRP) levels) were also considered. METHODS: Between March 2006 and December 2010, 283 CKDpatients were followed up for time-to-event analysis until the occurrence of fatal or nonfatal cardiovascular events. Endothelium-dependent vasodilatation (flow-mediated dilatation; FMD) and endothelium-independent vasodilatation (nitroglycerin-mediated dilatation) of the brachial artery were assessed noninvasively using high-resolution ultrasound. RESULTS: From the univariate analysis of FMD, it appears that a higher magnesium level is associated with less endothelial dysfunction. When a multivariate analysis was performed, magnesium and estimated glomerular filtration rates (eGFR) maintained a strong positive correlation with FMD, supporting the hypothesis that higher levels of magnesium may protect against endothelial damage. In univariate Cox proportional hazards models, FMD, magnesium, high sensitivity CRP, the HOMA index, eGFR, comorbid diabetes, hypertension, smoking status, systolic blood pressure, serum phosphate and intact parathormone emerged as significant predictors for cardiovascular outcomes. Kaplan-Meier curves showed significantly higher cardiovascular mortality rates in CKDpatients whose serum magnesium levels were below 2.05 mg/dl. CONCLUSIONS: This observational cohort study showed that magnesium may be an independent predictor of future cardiovascular outcomes and is the first study demonstrating such a role in etiologically diagnosed CKDpatients, across different stages.
Authors: Ioannis P Tzanakis; Elisavet E Stamataki; Antonia N Papadaki; Nektarios Giannakis; Nikolaos E Damianakis; Dimitrios G Oreopoulos Journal: Int Urol Nephrol Date: 2014-08-14 Impact factor: 2.370
Authors: Radojica V Stolic; Aleksandar N Jovanovic; Goran Z Trajkovic; Mirjana M Kostic; Andrijana M Odalovic; Sasa R Sovtic; Maja V Sipic; Slavica D Pajovic; Zorica N Sojevic-Timotijevic Journal: Int Urol Nephrol Date: 2016-01-18 Impact factor: 2.370
Authors: Yang Liu; Marie Fanelli Kuczmarski; Edgar R Miller; M Berenice Nava; Alan B Zonderman; Michele K Evans; Neil R Powe; Deidra C Crews Journal: J Ren Nutr Date: 2016-10-19 Impact factor: 3.655
Authors: Silvia Ferrè; Xilong Li; Beverley Adams-Huet; Naim M Maalouf; Khashayar Sakhaee; Robert D Toto; Orson W Moe; Javier A Neyra Journal: J Investig Med Date: 2019-03-02 Impact factor: 2.895
Authors: Baris Afsar; Mahmut Ilker Yilmaz; Dimitrie Siriopol; Hilmi Umut Unal; Mutlu Saglam; Murat Karaman; Mustafa Gezer; Alper Sonmez; Tayfun Eyileten; Ibrahim Aydin; Salih Hamcan; Yusuf Oguz; Adrian Covic; Mehmet Kanbay Journal: J Nephrol Date: 2016-04-02 Impact factor: 3.902